CD8A and cancer: It induced CD8+ and CD4+ T-cell responses and, importantly, was able to reduce the numbers of circulating regulatory T cells at the same time increasing immune infiltrates into solid tumors and their metastases prompting further development of TERT-based cancer vaccines (https://clinicaltrials.gov/ct2/show/NCT02301754 accessed on 12 February 2021 [68]).